Literature DB >> 18281839

Complementary and alternative medicine in the treatment of anxiety and depression.

Gill van der Watt1, Jonathan Laugharne, Aleksandar Janca.   

Abstract

PURPOSE OF REVIEW: There is well documented evidence for the increasing widespread use of complementary and alternative medicine in the treatment of physical and psychiatric symptoms and disorders within Western populations. Here we provide a review of the recent literature on evidence for using such interventions in the treatment of anxiety and depression. RECENT
FINDINGS: With regard to herbal treatments, kava is effective in reducing anxiety symptoms and St John's wort in treating mild to moderate depression. The association of kava with hepatotoxicity, however, is a significant concern. Promising data continue to emerge for the use of omega-3 fatty acids in managing depression. Evidence for the use of acupuncture in treating anxiety disorders is becoming stronger, although there is currently minimal empirical evidence for the use of aromatherapy or mindfulness-based meditation.
SUMMARY: The evidence base for the efficacy of the majority of complementary and alternative interventions used to treat anxiety and depression remains poor. Recent systematic reviews all point to a significant lack of methodologically rigorous studies within the field. This lack of evidence does not diminish the popularity of such interventions within the general Western population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281839     DOI: 10.1097/YCO.0b013e3282f2d814

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  36 in total

Review 1.  Quality of life in panic disorder: looking beyond symptom remission.

Authors:  Julia Davidoff; Scott Christensen; David N Khalili; Jaidyn Nguyen; Waguih William IsHak
Journal:  Qual Life Res       Date:  2011-09-21       Impact factor: 4.147

2.  The CB₁ receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin.

Authors:  Parichehr Hassanzadeh; Anna Hassanzadeh
Journal:  Neurochem Res       Date:  2012-02-07       Impact factor: 3.996

Review 3.  Electroacupuncture in the treatment of obesity.

Authors:  Fei Wang; De-Run Tian; Ji-Sheng Han
Journal:  Neurochem Res       Date:  2008-08-22       Impact factor: 3.996

4.  Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.

Authors:  W W IsHak; J Mirocha; D James; G Tobia; J Vilhauer; H Fakhry; S Pi; E Hanson; R Nashawati; E D Peselow; R M Cohen
Journal:  Acta Psychiatr Scand       Date:  2014-06-23       Impact factor: 6.392

5.  Feasibility of an interval, inspiration-triggered nocturnal odorant application by a novel device: a patient-blinded, randomised crossover, pilot trial on mood and sleep quality of depressed female inpatients.

Authors:  Frank Vitinius; Martin Hellmich; Annalena Matthies; Fabian Bornkessel; Heiner Burghart; Christian Albus; Karl-Bernd Huettenbrink; Julia Vent
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-05       Impact factor: 2.503

6.  The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders.

Authors:  Parichehr Hassanzadeh; Elham Arbabi; Fatemeh Atyabi; Rassoul Dinarvand
Journal:  Psychopharmacology (Berl)       Date:  2016-01-18       Impact factor: 4.530

7.  Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential.

Authors:  Parichehr Hassanzadeh; Anna Hassanzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-04-27       Impact factor: 4.530

8.  Patient-reported functioning in major depressive disorder.

Authors:  Waguih William IsHak; David M James; James Mirocha; Haidy Youssef; Gabriel Tobia; Sarah Pi; Katherine L Collison; Robert M Cohen
Journal:  Ther Adv Chronic Dis       Date:  2016-03-31       Impact factor: 5.091

Review 9.  New Botanical Anxiolytics for Use in Companion Animals and Humans.

Authors:  Rui Liu; Fida Ahmed; Christian Cayer; Martha Mullally; Ana Francis Carballo; Marco Otarola Rojas; Mario Garcia; John Baker; Aleksandar Masic; Pablo E Sanchez; Luis Poveda; Zul Merali; Tony Durst; John T Arnason
Journal:  AAPS J       Date:  2017-09-11       Impact factor: 4.009

10.  Improving Quality of Life for Patients with Major Depressive Disorder by Increasing Hope and Positive Expectations with Future Directed Therapy (FDT).

Authors:  Jennice S Vilhauer; Julissa Cortes; Nazanin Moali; Sally Chung; James Mirocha; Waguih William Ishak
Journal:  Innov Clin Neurosci       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.